HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study.

AbstractBACKGROUND:
Serum protein profiles have been investigated frequently to discover early biomarkers for breast cancer. So far, these studies used biological samples collected at or after diagnosis. This may limit these studies' value in the search for cancer biomarkers because of the often advanced tumor stage, and consequently risk of reverse causality. We present for the first time pre-diagnostic serum protein profiles in relation to breast cancer, using the Prospect-EPIC (European Prospective Investigation into Cancer and nutrition) cohort.
METHODS:
In a nested case-control design we compared 68 women diagnosed with breast cancer within three years after enrollment, with 68 matched controls for differences in serum protein profiles. All samples were analyzed with SELDI-TOF MS (surface enhanced laser desorption/ionization time-of-flight mass spectrometry). In a subset of 20 case-control pairs, the serum proteome was identified and relatively quantified using isobaric Tags for Relative and Absolute Quantification (iTRAQ) and online two-dimensional nano-liquid chromatography coupled with tandem MS (2D-nanoLC-MS/MS).
RESULTS:
Two SELDI-TOF MS peaks with m/z 3323 and 8939, which probably represent doubly charged apolipoprotein C-I and C3a des-arginine anaphylatoxin (C3adesArg), were higher in pre-diagnostic breast cancer serum (p = 0.02 and p = 0.06, respectively). With 2D-nanoLC-MS/MS, afamin, apolipoprotein E and isoform 1 of inter-alpha trypsin inhibitor heavy chain H4 (ITIH4) were found to be higher in pre-diagnostic breast cancer (p < 0.05), while alpha-2-macroglobulin and ceruloplasmin were lower (p < 0.05). C3a(desArg) and ITIH4 have previously been related to the presence of symptomatic and/or mammographically detectable breast cancer.
CONCLUSIONS:
We show that serum protein profiles are already altered up to three years before breast cancer detection.
AuthorsAnnemieke W J Opstal-van Winden, Esmeralda J M Krop, Monica H Kåredal, Marie-Christine W Gast, Christian H Lindh, Marina C Jeppsson, Bo A G Jönsson, Diederick E Grobbee, Petra H M Peeters, Jos H Beijnen, Carla H van Gils, Roel C H Vermeulen
JournalBMC cancer (BMC Cancer) Vol. 11 Pg. 381 (Aug 26 2011) ISSN: 1471-2407 [Electronic] England
PMID21871081 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers, Tumor
Topics
  • Aged
  • Biomarkers, Tumor (blood)
  • Breast Neoplasms (diagnosis)
  • Case-Control Studies
  • Female
  • Humans
  • Middle Aged
  • Proteomics
  • Risk Factors
  • Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: